

3 June 2021

This letter (**Letter**) should be read in conjunction with the scheme document circulated to shareholders of Immunodiagnostic Systems Holdings PLC (**Company**) dated on or around the date of this Letter (**Scheme Document**), a copy of which is enclosed with this Letter. The Scheme Document (together with a copy of this Letter) can also be viewed on IDS's website at <https://www.idsplc.com/investorrelations/>.

To: Holders of Option(s) (**Optionholders**) under the IDS Unapproved Share Option Scheme (the **Plan**)

Dear Optionholder

**Recommended cash offer for IDS by PerkinElmer (UK) Holdings Limited (PerkinElmer UK) to be effected by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006**

As you may know, on 17 May 2021, the boards of PerkinElmer, Inc. and IDS announced that they had agreed the terms of a recommended all cash offer for the entire issued and to be issued ordinary share capital of IDS by PerkinElmer UK (and/or such other nominee(s) of PerkinElmer UK as it may determine) (**Acquisition**). The Acquisition is intended to be effected by means of a Court-sanctioned "scheme of arrangement" under Part 26 of the Companies Act 2006 (the **Scheme**). The date the Scheme is expected to be sanctioned by the Court is to be confirmed but is expected to be 8 July 2021 (the **Sanction Date**). The purpose of the Scheme is to enable PerkinElmer UK to become the owner of the entire issued and to be issued ordinary share capital of the Company.

You are receiving this Letter as you hold an option granted under the Plan (**Option**). The details of your Option are set out in the statement enclosed with this Letter (the **Option Statement**) and the remainder of this Letter explains the effect of the Acquisition on your Option.

Your Option was granted subject to (i) the rules of the Plan and (ii) the exercise condition set out in the option documentation provided to you when your Option was granted (**Exercise Condition**). As the Exercise Condition has not been met, your Option has not become exercisable and it will lapse in full at the end of the six month period commencing on the Sanction Date, in accordance with the rules of the Plan. As a result, you will not be entitled to exercise your Option to acquire any shares of the Company in connection with the Acquisition.

If for any reason the Scheme is not sanctioned by the Court, your Option will continue to subsist in accordance with the rules of the Plan, but it will remain the case that your Option will not be capable of exercise and will lapse in due course.

You do not need to take any action as your Option will automatically lapse in full at the end of the six month period commencing on the Sanction Date.

If you have any queries in relation to this Letter please contact [REDACTED] at the Company by email at [REDACTED]

**The Company and its officers and employees may not provide you with any legal, tax or financial advice. If you are in any doubt as to the contents of this letter you should seek your own financial advice from an independent professional advisor as soon as possible.**

Yours faithfully

A solid black rectangular box used to redact a signature.

For and on behalf of Immunodiagnostic Systems Holdings PLC